ARID1A and ovarian carcinoma: Furthermore, inhibition of the EZ2H methylesterase in ARID1A mutated ovarian cancer cells results in synthetic lethality, suggesting EZ2H as a potential new therapeutic target for ARID1A mutated tumours [80,81,82,83].